lmlifidase treatment tor acute inflammation in AQP4-lgG associated neuromyelitis optica spectrum disorder (DEFEAT NMOSD)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517176-38-00

Acronym

NL80681.078.22

Enrollment

Registered

2024-09-10

Start date

Unknown

Completion date

Unknown

Last updated

2024-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neuromyelitis optica spectrum disorder, devic disease

Brief summary

The proportion of participants with a depletion of circulating pathogenie anti-AQP4 lgG antibodies, below detection limits as measured with a state-of-the-arts cell-based assay in the timeframe within 6h after treatment.

Interventions

DRUGIdefirix 11 mg powder for concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The proportion of participants with a depletion of circulating pathogenie anti-AQP4 lgG antibodies, below detection limits as measured with a state-of-the-arts cell-based assay in the timeframe within 6h after treatment.	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026